TTM
$8.20B
YoY change
+17.9%
5Y CAGR
+8.8%
Peak year (2021)
$9.20B
Cumulative operating income
$153.38B
Operating Income history chart for Abbott Laboratories (ABT) from 1985 to 2025
Latest: $8.05B
Operating Income growth chart for Abbott Laboratories (ABT) from 1985 to 2025
Latest: +17.9%
Operating Income history table for Abbott Laboratories (ABT) from 1985 to 2025
| 2025 | $8.05B | +17.9% | +$1.22B | ||
| 2024 | $6.83B | +6.1% | +$390.00M | ||
| 2023 | $6.43B | -23.0% | −$1.93B | ||
| 2022 | $8.36B | -9.1% | −$838.00M | ||
| 2021 | $9.20B | +73.9% | +$3.91B | ||
| 2020 | $5.29B | +15.2% | +$700.00M | ||
| 2019 | $4.59B | +19.4% | +$747.00M | ||
| 2018 | $3.84B | +94.9% | +$1.87B | ||
| 2017 | $1.97B | -39.3% | −$1.28B | ||
| 2016 | $3.25B | +10.2% | +$300.00M | ||
| 2015 | $2.95B | +1.1% | +$33.00M | ||
| 2014 | $2.92B | +35.9% | +$770.00M | ||
| 2013 | $2.15B | +6.9% | +$139.00M | ||
| 2012 | $2.01B | -70.7% | −$4.83B | ||
| 2011 | $6.84B | -3.0% | −$209.33M | ||
| 2010 | $7.05B | +7.3% | +$480.04M | ||
| 2009 | $6.57B | +7.9% | +$481.65M | ||
| 2008 | $6.09B | +23.1% | +$1.14B | ||
| 2007 | $4.95B | +14.1% | +$609.33M | ||
| 2006 | $4.34B | -6.7% | −$313.18M | ||
| 2005 | $4.65B | +11.3% | +$472.07M | ||
| 2004 | $4.18B | +40.5% | +$1.20B | ||
| 2003 | $2.97B | -5.6% | −$177.93M | ||
| 2002 | $3.15B | +66.4% | +$1.26B | ||
| 2001 | $1.89B | -44.3% | −$1.51B | ||
| 2000 | $3.40B | +8.0% | +$251.20M | ||
| 1999 | $3.15B | +1.0% | +$31.45M | ||
| 1998 | $3.12B | +9.4% | +$267.50M | ||
| 1997 | $2.85B | +8.9% | +$233.37M | ||
| 1996 | $2.62B | +9.8% | +$234.16M | ||
| 1995 | $2.38B | +11.1% | +$238.70M | ||
| 1994 | $2.14B | +11.4% | +$220.24M | ||
| 1993 | $1.92B | +26.1% | +$397.97M | ||
| 1992 | $1.53B | -2.0% | −$31.00M | ||
| 1991 | $1.56B | +10.7% | +$150.90M | ||
| 1990 | $1.41B | +15.1% | +$184.90M | ||
| 1989 | $1.22B | +10.8% | +$119.20M | ||
| 1988 | $1.10B | +9.6% | +$96.30M | ||
| 1987 | $1.01B | +14.5% | +$127.10M | ||
| 1986 | $878.60M | +19.2% | +$141.50M | ||
| 1985 | $737.10M | — | — |
- 2025$8.05B+17.9%
- 2024$6.83B+6.1%
- 2023$6.43B-23.0%
- 2022$8.36B-9.1%
- 2021$9.20B+73.9%
- 2020$5.29B+15.2%
- 2019$4.59B+19.4%
- 2018$3.84B+94.9%
- 2017$1.97B-39.3%
- 2016$3.25B+10.2%
- 2015$2.95B+1.1%
- 2014$2.92B+35.9%
- 2013$2.15B+6.9%
- 2012$2.01B-70.7%
- 2011$6.84B-3.0%
- 2010$7.05B+7.3%
- 2009$6.57B+7.9%
- 2008$6.09B+23.1%
- 2007$4.95B+14.1%
- 2006$4.34B-6.7%
- 2005$4.65B+11.3%
- 2004$4.18B+40.5%
- 2003$2.97B-5.6%
- 2002$3.15B+66.4%
- 2001$1.89B-44.3%
- 2000$3.40B+8.0%
- 1999$3.15B+1.0%
- 1998$3.12B+9.4%
- 1997$2.85B+8.9%
- 1996$2.62B+9.8%
- 1995$2.38B+11.1%
- 1994$2.14B+11.4%
- 1993$1.92B+26.1%
- 1992$1.53B-2.0%
- 1991$1.56B+10.7%
- 1990$1.41B+15.1%
- 1989$1.22B+10.8%
- 1988$1.10B+9.6%
- 1987$1.01B+14.5%
- 1986$878.60M+19.2%
- 1985$737.10M—
Operating Income values are taken from Abbott Laboratories's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Income at Abbott Laboratories (ABT)
According to Abbott Laboratories's latest reported financial statements, the company's current operating income (TTM) is $8.20B. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
In 2025, Abbott Laboratories (ABT) operating income totalled $8.05B – grew 17.9% year-over-year.
Over 2020–2025 (5 years), Abbott Laboratories operating income expanded at a +8.8% compound annual rate, sustaining 2 straight years of year-over-year growth.
Between 2021 and 2025, Abbott Laboratories operating income declined 12.5%, falling from $9.20B to $8.05B.
$9.20B stands as the all-time-high annual operating income, posted in 2021, against a low of $737.10M during 1985.
Abbott Laboratories Operating Income by Year
Abbott Laboratories Operating Income 2025: $8.05B
In 2025, Abbott Laboratories reported operating income of $8.05B, grew 17.9% from 2024.
Abbott Laboratories Operating Income 2024: $6.83B
Abbott Laboratories operating income in 2024 was $6.83B, grew 6.1% from 2023.
Abbott Laboratories Operating Income 2023: $6.43B
2023's operating income for Abbott Laboratories came in at $6.43B, declined 23.0% below 2022.
Abbott Laboratories Operating Income 2022: $8.36B
Abbott Laboratories posted operating income of $8.36B in 2022, declined 9.1% below 2021.
Abbott Laboratories Operating Income 2021: $9.20B
Abbott Laboratories operating income in 2021 was $9.20B.
See more financial history for Abbott Laboratories (ABT).
Sector peers by Operating Income
Healthcare peers of Abbott Laboratories (ABT), ranked by their latest operating income
| $29.70B | |
| $25.60B | |
| $23.49B | |
| $20.09B | |
| $19.90B | |
| $18.96B | |
| $13.74B | |
| $10.68B |
- $29.70B
- $25.60B
- $23.49B
- $20.09B
- $19.90B
- $18.96B
- $13.74B
- $10.68B
Frequently asked questions
Abbott Laboratories (ABT) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation